EFFICACY OF THE SLEEVE GASTROPLASTY WITH THE ENDOSCOPIC SYSTEM OVERSTICH SX ON WEIGHT LOSS AND REDUCTION OF CO-MORBIDITY FOR OBESE PATIENTS

NCT ID: NCT05072067

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-14

Study Completion Date

2023-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The OverStitch ™ Sx System (Apollo Endosurgery Inc., Austin, Tx, Usa) is a new generation of endoscopic suturing device. It is inserted into an endoscope allowing the approximation of Luc Karsentys soft tissue by placement of sutures. It is as effective a suture system as a surgical system. The OverStitch ™ Sx allows suturing in the upper and lower GI with a flexible single channel endoscope. Previously, the ™ Overstich was only compatible with an Olympus dual channel endoscope.

Thus, a wide range of interventions are possible, including gastric endoplastic sleeve (ESG), RYGB revision, anastomotic fistula repair and / or sleeve revision. In each of these indications, the OverStitch (OverStitch) ™ system has shown its effectiveness and safety.

The OverStitch Endoscopic ™ Suture System allows the entire digestive wall to be sutured through a flexible endoscope. Thus, a wide range of interventions are possible, including gastric pocket repair after gastric bypass surgery, anastomotic fistula repair, endoscopic treatment of digestive perforation, and endoscopic sleeve surgery. In each of these indications, the OverStitch system has demonstrated its effectiveness and safety. But this technique is recent, especially in France. In addition, no data has yet been released regarding the new Overstitch ™ Sx device compatible with all single channel endoscopes.

An observational study including patients in French centers that are experts in therapeutic endoscopy seems essential to us to better assess this new device and this new technique in practice

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OBESE PATIENT

OverStitch™ Sx with a Single channel endoscop CO2 Insufflation, patient on decubitus dorsal, with intubate 3 to 7 sutures, from the antral ogiv to the cardia are done

Group Type EXPERIMENTAL

the sleeve gastroplasty with the endoscopic system Overstich SX

Intervention Type PROCEDURE

the sleeve gastroplasty with the endoscopic system Overstich SX

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

the sleeve gastroplasty with the endoscopic system Overstich SX

the sleeve gastroplasty with the endoscopic system Overstich SX

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18, male or female
* Patient with obesity with a BMI\> 30 or BMI\> 40 (if surgery contraindicated or refused by the patient)
* Patient with a weight gain after sleeve gastroplasty or sleeve gastrectomy
* Informed and written consent of the patient obtained
* Complete clinical examination
* Lack of participation in another clinical study
* Patient able to follow, understand the study and answer the questionnaire

Exclusion Criteria

* Haemorrhagic disease, haemostasis and coagulation disorder and platelets \<60000 / mm3).
* Breastfeeding women
* Toxicomany, alcoolism
* Patient known for gastric lesion requiring surveillance or familial history of gastric neoplasia
* Hiatus hernia\> 4 cm high
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinique du Trocadéro

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique Du Trocadero

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A01562-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ESG in Obese Adolescents
NCT06914765 ENROLLING_BY_INVITATION NA
RESCUE: Discontinuation of GLP-1
NCT07190794 RECRUITING
ULTIMATE Study for Weight Loss
NCT01771276 COMPLETED NA
EGPSS for Weight Management in an in Vivo Human Model
NCT07186959 ENROLLING_BY_INVITATION NA
ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)
NCT05578703 ACTIVE_NOT_RECRUITING NA